Peroxisome proliferator-activated receptor-γ 34C>G polymorphism and colorectal cancer risk: A meta-analysis

Por Lu, Yong-Liang, Li, Gai-Ling, Huang, Hui-Lian, Zhong, Jing, Dai, Li-Cheng
Publicado em 2010

Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects

Por Li, Gai Ling, Winter, Helen, Arends, Rosalin, Jay, Gary W, Le, Vu, Young, Tim, Huggins, John P
Publicado em 2012

The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib

Por Mao, Wei-feng, Shao, Min-hua, Gao, Pin-ting, Ma, Ji, Li, Hui-juan, Li, Gai-ling, Han, Bao-hui, Yuan, Chong-gang
Publicado em 2012

Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C

Por Wang, He-chuan, Ren, Yu-peng, Qiu, Yue, Zheng, Jenny, Li, Gai-ling, Hu, Chuan-pu, Zhou, Tian-yan, Lu, Wei, Li, Liang
Publicado no Acta Pharmacol Sin (2018)